Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20
about
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes.High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Current status of targeted therapies for mantle cell lymphoma.The MS4A family: counting past 1, 2 and 3.Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.Mapping cytoskeletal protein function in cells by means of nanobodies.Molecular action of lenalidomide in lymphocytes and hematologic malignanciesLow-dose ofatumumab for rituximab-resistant nephrotic syndrome.Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia.Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment.Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.Clinical trials in minimal change disease.Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling.Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity
P2860
Q30764873-4F995AE6-FF4C-477A-B696-8CA478EF0F39Q33667654-DB8E35A1-91F5-4405-B73C-B2A82E25F4CEQ34438836-23B5C368-96CF-4A65-8DE3-0E392E06E068Q36211450-22C43B45-59C6-4567-9896-9E585423729FQ36770915-78F1B1CA-E6ED-4B0C-AA36-B1FBFC2DC76AQ37676785-ABFA1AD9-0918-4E00-87E7-1E86598AC9F9Q37810901-B7EAD673-D312-4B38-9593-C7A02F82B626Q37913356-CC49F9E1-4A31-4B10-AC33-2461DA4C5765Q37956405-82183387-9C3B-4ACB-B4B7-0C6BE3C3DA1AQ38401877-07113FA3-797D-4735-8213-92CE602ECF78Q38632940-83F093DF-C46A-4680-9079-A6204A431F6DQ38665518-34878829-5EA8-4B45-AB92-9F4B2AF70E43Q39131836-865D1A9D-991F-4C2F-85C7-7A4C6733151BQ39570166-34227CE2-1A55-4809-9CAD-3F4805687900Q41728530-9AD993D4-2E25-4993-AEEE-5D557F35C6D9Q41966195-F0E13721-6336-4181-B7B2-20DA9DB700E9Q42265792-6A53D913-5E84-4F55-A74B-657086A1741AQ42358628-B4C34386-8569-41EA-A3A6-6CB222740BEEQ50047399-D407A284-5257-401A-8713-DACCF48FF022Q53368686-1CBADEF1-B0C6-4514-A60E-62FE2C901402Q55278753-6AE3A1C4-BF42-4648-B63F-CA2E7479BBF4Q56908538-169F4185-7290-4CB9-990B-208468F1807A
P2860
Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Structure of the Fab fragment ...... ecognition mechanism with CD20
@ast
Structure of the Fab fragment ...... ecognition mechanism with CD20
@en
Structure of the Fab fragment ...... ecognition mechanism with CD20
@nl
type
label
Structure of the Fab fragment ...... ecognition mechanism with CD20
@ast
Structure of the Fab fragment ...... ecognition mechanism with CD20
@en
Structure of the Fab fragment ...... ecognition mechanism with CD20
@nl
prefLabel
Structure of the Fab fragment ...... ecognition mechanism with CD20
@ast
Structure of the Fab fragment ...... ecognition mechanism with CD20
@en
Structure of the Fab fragment ...... ecognition mechanism with CD20
@nl
P2093
P1433
P1476
Structure of the Fab fragment ...... ecognition mechanism with CD20
@en
P2093
Jianping Ding
P304
P356
10.1016/J.MOLIMM.2009.04.009
P50
P577
2009-05-08T00:00:00Z